Pacira BioSciences (NASDAQ:PCRX – Get Rating) had its target price reduced by Piper Sandler from $63.00 to $62.00 in a research report sent to investors on Tuesday morning, The Fly reports. Other equities research analysts have also issued reports about the company. StockNews.com started coverage on Pacira BioSciences in a research report on Thursday, March […]
Pacira BioSciences (NASDAQ:PCRX – Get Rating)‘s stock had its “buy” rating reissued by Needham & Company LLC in a report issued on Thursday, Benzinga reports. They currently have a $60.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside of 29.00% from the company’s previous close. PCRX has […]
Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) has been given a consensus rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target […]
Wesbanco Bank Inc. bought a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 10,503 shares of the company’s stock, valued at approximately $406,000. A number of other hedge funds have also added […]
Rhumbline Advisers boosted its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) by 7.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 125,635 shares of the company’s stock after acquiring an additional 8,623 shares during the quarter. Rhumbline […]